Rafael Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023
March 14, 2023 at 04:45 pm EDT
Share
Rafael Holdings, Inc. reported earnings results for the second quarter and six months ended January 31, 2023. For the second quarter, the company reported sales was USD 0.07 million compared to USD 0.074 million a year ago. Revenue was USD 0.07 million compared to USD 0.074 million a year ago. Net loss was USD 3.25 million compared to USD 2.32 million a year ago. Basic loss per share from continuing operations was USD 0.13 compared to USD 0.09 a year ago. Basic loss per share was USD 0.14 compared to USD 0.12 a year ago.
For the six months, sales was USD 0.14 million compared to USD 0.145 million a year ago. Revenue was USD 0.14 million compared to USD 0.265 million a year ago. Net loss was USD 1.66 million compared to USD 114.35 million a year ago. Basic loss per share from continuing operations was USD 0.36 compared to USD 5.86 a year ago. Basic loss per share was USD 0.08 compared to USD 5.91 a year ago.
Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies. The Company's segments include healthcare and real estate. The Company's investments include Cornerstone Pharmaceuticals, Inc., which is a cancer metabolism-based therapeutics company; LipoMedix Pharmaceuticals Ltd., which is a clinical-stage pharmaceutical company; Barer Institute Inc., which is a preclinical cancer metabolism research operation; Cyclo Therapeutics Inc., which is a clinical-stage biotechnology company dedicated to developing medicines for patients and families living with diseases through its therapeutic asset like Trappsol and Cyclo; Day Three Labs, Inc., which offers pharmaceutical-grade technology like Unlokt, and Rafael Medical Devices, LLC, which is an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries. Its real estate segment comprises of a portion of a commercial building in Israel.